CLINICAL TRIALS PROFILE FOR TOPOTECAN

505(b)(2) Clinical Trials for TOPOTECAN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	St. Jude Children's Research Hospital	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination	NCT04661852 ↗	Cabozantinib With Topotecan-Cyclophosphamide	Recruiting	Dana-Farber Cancer Institute	Phase 1	2020-12-23	This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

All Clinical Trials for TOPOTECAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001333 ↗	Phase I Study of Intrathecal Topotecan	Completed	National Cancer Institute (NCI)	Phase 1	1993-02-01	The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
NCT00001335 ↗	New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-04-01	The prognosis for patients with metastatic Ewing's sarcoma family of tumors (ESF), rhabdomyosarcoma (RMS), and neuroblastoma (NBL) remains dismal, with less than 25% long-term disease-free survival. Though less grave, the prognosis for cure for other high-risk patients is approximately 50%. New treatment strategies, including the identification of highly active new agents, maximizing the dose intensity of the most active standard drugs, and the development of improved methods of consolidation to eradicate microscopic residual disease, are clearly needed to improve the outcome of these patients. This protocol will address these issues by commencing with a Phase II window, for the highest risk patients, to evaluate a series of promising drugs with novel mechanisms of action. All patients will then receive 5 cycles of dose-intensive "best standard therapy" with doxorubicin (adriamycin), vincristine, and cyclophosphamide (VAdriaC). Patients at high risk of relapse will continue onto a phase I consolidation regimen consisting of three cycles of dose-escalated Melphalan, Ifosfamide, Mesna, and Etoposide (MIME). Peripheral blood stem cell transfusions (PBSCT) and recombinant human G-CSF will be used as supportive care measures to allow maximal dose-escalation of this combination regimen.
NCT00002395 ↗	Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)	Completed	SmithKline Beecham	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give topotecan through a vein to treat HIV-infected patients with PML, an opportunistic (AIDS-related) infection caused by a virus that infects brain tissue and causes damage to the brain and the spinal cord. Topotecan fights HIV and the JC virus (the virus that causes PML) in laboratory experiments.
NCT00002515 ↗	Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1992-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa, carboplatin, and topotecan followed by bone marrow transplantation in treating patients who have metastatic or progressive rare cancer.

Clinical Trial Conditions for TOPOTECAN

Condition Name

Condition Name for TOPOTECAN
Intervention	Trials
Ovarian Cancer	81
Neuroblastoma	42
Small Cell Lung Cancer	39
Lung Cancer	31

Condition MeSH

Condition MeSH for TOPOTECAN
Intervention	Trials
Small Cell Lung Carcinoma	108
Ovarian Neoplasms	100
Lung Neoplasms	97
Carcinoma, Ovarian Epithelial	80

Clinical Trial Locations for TOPOTECAN

Trials by Country

Trials by Country for TOPOTECAN
Location	Trials
China	90
Australia	88
United Kingdom	79
Germany	73
Italy	68

Trials by US State

Trials by US State for TOPOTECAN
Location	Trials
California	112
New York	103
Texas	100
Ohio	100
Florida	94

Clinical Trial Progress for TOPOTECAN

Clinical Trial Phase

Clinical Trial Phase for TOPOTECAN
Clinical Trial Phase	Trials
PHASE3	22
PHASE2	11
PHASE1	5

Clinical Trial Status

Clinical Trial Status for TOPOTECAN
Clinical Trial Phase	Trials
Completed	243
Recruiting	72
Terminated	44

Clinical Trial Sponsors for TOPOTECAN

Sponsor Name

Sponsor Name for TOPOTECAN
Sponsor	Trials
National Cancer Institute (NCI)	139
GlaxoSmithKline	62
Children's Oncology Group	16

Sponsor Type

Sponsor Type for TOPOTECAN
Sponsor	Trials
Other	441
Industry	252
NIH	144

Last updated: July 27, 2026

Topotecan clinical trials update, market analysis, and market projection (2026-2036)

Topotecan has ongoing development activity focused on combination regimens and next-generation delivery approaches, while the marketed competitive landscape remains dominated by branded and generic intraveneous (IV) and oral supply chains. Commercial growth is constrained by low overall incidence, patent and regulatory maturity, and pricing pressure from generics, including biosystem agnostic small-molecule competition. Market outlook hinges on (1) trial readouts that expand label scope, (2) regional reimbursement, and (3) the penetration of IV-to-oral or reduced-administration formulations if any receive approvals.

What is the latest clinical trials update for topotecan in 2024-2026?

Which trial phases are active for topotecan combinations

Topotecan development in recent years has emphasized combination oncology strategies, most commonly in:

• Ovarian cancer (e.g., platinum-resistant settings)
• Small-cell lung cancer (SCLC)
• Cervical cancer (as monotherapy/combinations depending on setting)

Clinical trial activity pattern: most new starts aim to refine lines of therapy rather than replace standard of care. Outcome endpoints tend to focus on progression-free survival (PFS), overall response rate (ORR), and overall survival (OS), with safety reporting centered on neutropenia, febrile neutropenia, anemia, thrombocytopenia, and GI toxicities.

What are the dominant investigation themes

High-intent themes for active and recently reported programs include:

• Biomarker-stratified cohorts to improve response rates
• Addition of immune checkpoint inhibitors to topotecan backbone regimens in SCLC and other solid tumors
• Incorporation of targeted agents or PARP-pathway modifiers in ovarian cancer contexts
• Dose-intensity and supportive-care strategies to reduce hematologic toxicity

How to interpret trial updates for commercial impact

A trial is commercially material when it delivers:

• Statistically significant PFS or OS in a label-relevant population, or
• A compelling subgroup signal that supports label expansion, or
• A differentiated regimen that earns guideline inclusion.

If trials remain non-confirmatory, market effects are limited because topotecan is already widely available as generic IV and is mature from a regulatory and payer standpoint.

How big is the global topotecan market, and where does revenue come from?

Market revenue drivers

Topotecan revenue is driven by:

• Use in recurrent ovarian cancer and SCLC after prior therapy
• Regional chemotherapy prescribing patterns
• IV vs oral mix (where oral availability exists through the product supply chain and regulatory status)
• Generic pricing levels

What segments matter most

From a business planning perspective, split the market as:

• Indication: ovarian cancer vs SCLC vs cervical cancer use
• Form: IV products vs any oral presentation
• Region: US, EU5, UK, Japan, and rest of world (ROW)
• Pricing environment: branded legacy vs generic-dominant lanes

Topotecan market analysis by region: US, Europe, Japan, and emerging markets

United States

US demand is supported by:

• SCLC and recurrent ovarian cancer treatment volume
• Mature chemo-oncology infrastructure
• Generic penetration and contracting patterns that cap net price

US market performance is most sensitive to:

• Wholesale acquisition cost (WAC) revisions and pharmacy benefit contracting
• Any new labeling that increases access or extends use into new lines of therapy

Europe

European uptake is shaped by:

• National formulary decisions and oncology budgets
• Tendering, hospital procurement practices, and strict cost-effectiveness thresholds
• Replacement by alternative regimens when superior efficacy is established

Japan

Japan is typically less price sensitive at the wholesaler level than high-discount US markets, but volume is limited by incidence and reimbursement logic. Tender-like mechanisms in hospital settings still drive net pricing down over time.

Emerging markets

ROW growth depends on:

• Availability and distribution reliability
• Oncology center concentration
• Supportive care infrastructure affecting tolerability and dosing continuity

What are the key competitive dynamics for topotecan (branded vs generic vs pipeline differentiation)?

Why competition suppresses pricing

Topotecan is a mature small-molecule with broad generic availability. Competitive entry reduces net revenue through:

• Parallel substitution at the hospital level
• Contracting and tendering price pressure
• Reduced willingness to pay for marginal incremental convenience unless a clear clinical or administration advantage exists

Competitive set

Your competitive set is best framed as:

• Generic topotecan IV suppliers across key geographies
• Therapeutic alternatives in the same indications (other chemo regimens, checkpoint inhibitor backbones in SCLC, and targeted options in ovarian cancer)
• Any pipeline competitor if it achieves meaningfully better outcomes in second-line or later settings

When does topotecan lose exclusivity, and what does that mean for generic entry risk?

How exclusivity timing affects supply

Once patents and market exclusivity protections expire, the market becomes a pricing contest:

• Entry is faster and more frequent because manufacturing know-how and formulation approaches are commoditized
• Any remaining payer impact is mostly operational (availability and contract pricing) rather than IP-driven

Business implication

Post-exclusivity periods mainly change:

• Manufacturer mix (who wins supply contracts)
• Net realized price
• Inventory dynamics and shortages risk

What is the Orange Book status of topotecan and how does it affect market outlook?

Orange Book status governs:

• Patent barriers for generic approval and 180-day exclusivity for first filers
• Whether brand holders can delay competition through listed patents

For market projection and entry risk modeling, Orange Book listings inform:

• Which patents are still listed for the specific marketed strength and dosage forms
• Whether Paragraph IV challenges are likely to trigger settlement-based delay windows

What clinical trial readouts would change topotecan demand materially?

SCLC: what outcomes shift usage

Material readouts would show:

• Meaningful OS improvement or clear PFS benefit with manageable toxicity when combined with standard-of-care immunotherapy or targeted agents
• Subgroup benefit in biomarker-defined populations

If response rates rise but OS does not, uptake typically remains limited because payers and clinicians prioritize survival endpoints.

Ovarian cancer: what outcomes shift practice

In ovarian cancer, material changes include:

• Better outcomes in platinum-resistant cohorts vs existing regimens
• Improved tolerability profiles that enable higher dose intensity or longer treatment duration
• Supportive-care optimized dosing strategies that reduce severe neutropenia

How many ongoing topotecan trials exist, and what are the typical endpoints?

Trial count and endpoint concentration

A practical way to model pipeline risk without overcounting is to classify trials by:

• Regimen identity (topotecan alone vs combination)
• Setting (first-line, second-line, recurrent, platinum-resistant)
• Endpoint primary (PFS vs OS vs ORR)

Topotecan programs frequently use hematologic toxicity endpoints alongside ORR and PFS.

What formulations of topotecan are being developed (IV, oral, sustained-release, or novel delivery)?

Why formulation matters commercially

Formulation differentiation affects:

• Patient convenience
• Clinic chair-time and infusion capacity utilization
• Hospital pharmacy workflow
• Administration cost per treated patient

Even when efficacy is similar, delivery advantages can produce share shifts under constrained infusion capacity.

What to watch

• Any oral or less-frequent dosing development
• Any platform that reduces neutropenia risk or reduces monitoring burden
• Bioavailability improvements that support consistent exposure

What patent litigation or Paragraph IV activity affects topotecan market supply?

How litigation changes supply and pricing

Patent litigation affects:

• Whether specific generic entrants launch on time
• Whether settlements delay competition
• Whether multiple entrants compete for contracts, compressing net prices

From a market projection standpoint, the biggest drivers are:

• First generic entry timing
• Subsequent waves of additional applicants
• Settlement terms that alter launch timing per strength and dosage form

Topotecan market projection 2026-2036: base case, bull case, bear case

Core assumptions used for projection

• Indication demand remains stable with modest incidence-driven growth
• Net prices follow a downward trajectory due to generic penetration
• Uptake gains from trial readouts require label-relevant positive outcomes and inclusion in standard care
• Any new formulation approval would increase share only if it reduces administration burden without losing efficacy

Base case

• Volume grows low-to-mid single digits through 2030, mainly from:
  • Treatment growth in regions with increasing oncology capacity
  • Incremental line-of-therapy utilization in settings with ongoing unmet need
• Net price continues to fall modestly annually as contracting tightens
• Market grows slowly in value terms, with volume growth offset by price erosion

Bull case

• A label-expanding positive combination trial readout improves guideline inclusion
• A differentiated delivery system or supportive-care package improves patient throughput and tolerability
• Value growth outpaces volume due to partial price stabilization in less competitive lanes or better formulary retention

Bear case

• Trials fail to show survival or durable PFS benefits in label-relevant populations
• Net price compression accelerates due to additional generic waves
• Alternative therapies reduce topotecan share in recurrent ovarian cancer or SCLC

Commercial outlook by indication: where revenue should concentrate

Ovarian cancer

Revenue is driven by recurrence patterns and platinum-resistant management. Growth depends on:

• Whether combination regimens show clear superiority over standard salvage
• Whether toxicity management enables better adherence and longer treatment

Small-cell lung cancer

SCLC is sensitive to:

• Timing of immunotherapy integration
• OS/PFS shifts from new combinations
• Payer adoption of newer regimens that displace chemotherapy backbone therapy

Cervical cancer

Cervical cancer use is typically more constrained by specific guideline inclusion and regional practice differences. Any expanded niche could help, but broad market impact requires major readouts.

What generic entry risks exist for topotecan by dosage form and strength?

Entry risk map

• Highest risk: dosage strengths and presentations with the greatest generic pipeline density and clean switching economics
• Moderate risk: strengths with formulation complexity or manufacturing bottlenecks
• Lower risk: if any Orange Book-listed patents still block entry for specific product formats

Operational market effect

If multiple generics launch around the same time:

• Net prices fall faster
• Contracting shifts quickly
• Brand share declines

How does topotecan compare with other SCLC and ovarian cancer chemotherapies on market potential?

Market comparison logic

Topotecan’s market potential is typically lower than newer targeted or immunotherapy-heavy regimens because:

• It competes with agents offering survival gains
• Pricing pressure accelerates post-generic entry
• Clinical adoption depends on being a reliable salvage backbone rather than a primary standard

Still, topotecan can remain a durable option when:

• It is embedded in combination regimens that show consistent benefit
• Alternative agents have access barriers, high toxicity, or cost constraints

Key Takeaways

• Topotecan’s clinical pipeline is centered on combination regimens, with commercial impact contingent on label-relevant survival or durable PFS benefits.
• Market value growth is constrained by generic penetration and ongoing price compression dynamics.
• The largest upside is label expansion from positive trial readouts and any clinically differentiated delivery approach that reduces administration burden without sacrificing efficacy.
• The largest downside is accelerated net price erosion from additional generic waves and continued displacement by newer chemo-immunotherapy or targeted regimens in SCLC and ovarian cancer.

FAQs

What are the most important topotecan clinical endpoints that predict uptake?

PFS and OS in label-relevant lines of therapy, supported by ORR durability and manageable hematologic toxicity profiles.

Does topotecan use expand if a combination trial improves response rate only?

Usually limited. Without OS or durable PFS, uptake is often constrained to select subgroups or secondary preference settings.

How does generic pricing pressure affect topotecan hospital formulary decisions?

It drives switching to lowest net-cost options, often through tendering and contracting that favors multiple generic suppliers.

What is the biggest driver of topotecan market share in the next 3-5 years?

Supply contract pricing and any label-expanding approvals from combination trials that shift guideline inclusion.

Are formulation improvements a faster route to differentiation for topotecan than new clinical efficacy?

Yes, because administration convenience can influence adoption even with similar efficacy, but payer uptake still depends on safety and dosing practicality.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Topotecan studies and results. U.S. National Library of Medicine.
3. FDA labeling for topotecan-containing products. U.S. Food and Drug Administration.
4. EMA product information and assessments for topotecan-containing medicines. European Medicines Agency.